SAREPTA THERAPEUTICS, INC. Billed Contracts Receivable
SAREPTA THERAPEUTICS, INC. (SRPT) had Billed Contracts Receivable of $376.80 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › and Others
us-gaap:BilledContractReceivables · last filed 2026-08-05
- 2026-06-30: Billed Contracts Receivable $376.80M.
- 2026-03-31: Billed Contracts Receivable $394.80M.
- 2025-12-31: Billed Contracts Receivable $398.20M.
- 2025-09-30: Billed Contracts Receivable $395.70M.
| Period end | Billed Contracts Receivable | Billed Contracts Receivable as first filed |
|---|---|---|
| 2026-06-30 | $376.80M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $394.80M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $398.20M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $395.70M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $527.30M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $659.40M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $602.00M 10-Q · filed 2025-11-06 | |
| 2024-09-30 | $434.50M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $360.00M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $378.80M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $400.30M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $318.90M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $236.80M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $223.80M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $214.60M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $201.50M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $203.90M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $178.20M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $153.00M 10-K · filed 2023-02-28 | $152.99M 10-K · filed 2022-03-01 |
| 2021-09-30 | $149.32M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $127.05M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $117.73M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $100.87M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $104.49M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $94.69M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $89.96M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $90.41M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $67.26M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $56.19M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $49.72M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $48.25M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $47.81M 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $42.06M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $38.92M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $28.54M 10-K · filed 2019-02-28 | |
| 2017-09-30 | $23.82M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $16.86M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $11.35M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $4.00M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |